US Edition“Sustained” clinical benefits seen at six months in Altavalve early feasibility study - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
“Sustained” clinical benefits seen at six months in Altavalve early feasibility study - Cardiovascular News
Philippe Généreux Results of the Altavalve early feasibility study (EFS) evaluating outcomes of the AltaValve (4C Medical) sub-valvular transcatheter mitral valve replacement (TMVR) system have demonstrated sustained clinical benefits out to six months among high surgical risk patients treated for symptomatic severe mitral regurgitation (MR), with the haemodynamic performance of the valve maintained out to this timepoint. These were among the co…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
